Demonstration of response in rheumatoid arthritis patients who are nonresponders according to the American College of Rheumatology 20% criteria: the paradox of beneficial treatment effects in nonresponders in the ATTRACT trial. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy

Arthritis Rheum. 2001 Nov;44(11):2703-4. doi: 10.1002/1529-0131(200111)44:11<2703::aid-art451>3.0.co;2-e.
No abstract available

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / diagnostic imaging
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / immunology
  • Arthritis, Rheumatoid / physiopathology
  • Clinical Trials as Topic
  • Drug Therapy, Combination
  • Humans
  • Infliximab
  • Methotrexate / therapeutic use
  • Prednisolone / therapeutic use
  • Prognosis
  • Radiography
  • Severity of Illness Index
  • Sulfasalazine / therapeutic use
  • Treatment Outcome*
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Tumor Necrosis Factor-alpha / immunology

Substances

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Tumor Necrosis Factor-alpha
  • Sulfasalazine
  • Prednisolone
  • Infliximab
  • Methotrexate